Cargando…
Corrigendum: Suppression of Spry1 inhibits triple-negative breast cancer malignancy by decreasing EGF/EGFR mediated mesenchymal phenotype
Autores principales: | He, Qing, Jing, Hongyu, Liaw, Lucy, Gower, Lindsey, Vary, Calvin, Hua, Shucheng, Yang, Xuehui |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5411808/ https://www.ncbi.nlm.nih.gov/pubmed/28462917 http://dx.doi.org/10.1038/srep46791 |
Ejemplares similares
-
Suppression of Spry1 inhibits triple-negative breast cancer malignancy by decreasing EGF/EGFR mediated mesenchymal phenotype
por: He, Qing, et al.
Publicado: (2016) -
Suppression of Spry4 enhances cancer stem cell properties of human MDA-MB-231 breast carcinoma cells
por: Jing, Hongyu, et al.
Publicado: (2016) -
Erratum to: Suppression of Spry4 enhances cancer stem cell properties of human MDA-MB-231 breast carcinoma cells
por: Jing, Hongyu, et al.
Publicado: (2017) -
Spry1 and Spry4 Differentially Regulate Human Aortic Smooth Muscle Cell Phenotype via Akt/FoxO/Myocardin Signaling
por: Yang, Xuehui, et al.
Publicado: (2013) -
Corrigendum to: DDEL-17. TRIPLE INTRAVENTRICULAR CHEMOTHERAPY FOR TREATMENT OF RELAPSED CHOROID PLEXUS CARCINOMA
Publicado: (2023)